# Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

> **NCT02207088** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 68 (actual)

## Conditions studied

- Chronic Hepatitis C
- Hepatitis C Virus
- Compensated Cirrhosis
- Severe Renal Impairment
- End-stage Renal Disease

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir
- **DRUG:** dasabuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02207088
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-23
- **Primary completion:** 2016-12-06
- **Final completion:** 2016-12-06
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207088, "Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02207088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*